Function Health's $450M Financing: Why the Deal Didn't Move Its $2.5B Valuation

Function Health secured $450 million from General Catalyst on July 30, 2026 — but its $2.5 billion valuation from November 2025 didn't move, because the deal isn't an equity round at all.

The financing, reported by Fierce Healthcare and confirmed in a PR Newswire release, comes from General Catalyst's Customer Value Fund (CVF) — a vehicle designed to fund customer acquisition and growth against future revenue, rather than take a priced equity stake. That distinction is the whole story: a headline-sized check that, by design, left Function's cap table and valuation untouched.

Function Health Valuation 2026: Why $450M Didn't Reset It

Function Health's valuation is $2.5 billion, set by a $298 million Series B in November 2025. The July 30, 2026 financing from General Catalyst's Customer Value Fund is structured as non-dilutive, revenue-linked capital: General Catalyst provides cash Function can deploy against growth, and gets repaid (with a return) out of the revenue that growth generates, rather than owning a slice of the company priced at a new valuation. No new equity was issued, so there was no new share price to set — a mechanical reason the $2.5 billion figure simply carried forward.

Equity vs. Customer Value Fund Financing: What Actually Changed

The two Function Health raises in less than nine months look similar in press coverage but work completely differently under the hood.

Sources: MedCity News and MobiHealthNews on the CVF structure and Series B terms. All figures as of September 2026.

What Function Health Actually Sells

Function Health runs a membership model built around routine, comprehensive lab testing: $365 per year covers two rounds of blood testing across more than 160 biomarkers, with access to MRI and CT imaging at more than 200 partner locations to screen for cancer, aneurysms, strokes, and other conditions before symptoms appear. Co-founder Dr. Mark Hyman's public profile and a roster of celebrity investors have helped fuel a waitlist-driven growth model uncommon among healthcare startups.

Independent research firm Sacra estimated Function reached a $100 million annualized revenue run rate by February 2025 — up 450% year-over-year at the time — on roughly 200,000 subscribers. Function has since disclosed more than 500,000 members as of mid-2026, more than double that subscriber count, though the company has not published an updated revenue run-rate figure to match.

Function Health vs. Neko Health: Two Bets on Preventive Care

Function isn't the best-funded company in preventive health. Neko Health, the Stockholm-based full-body scanning startup co-founded by Spotify's Daniel Ek, carries a valuation roughly 3x higher on a very different model.

Sources: Startup Riders' "$3B Preventive Health Race" analysis and New Market Pitch's 2026 longevity startup valuation rankings. Neko Health valuation reflects its most recent disclosed raise as of 2026.

Function's per-member price is roughly 5x cheaper than the hardware-led scanning experience Neko charges for in its own clinics.

What the headline misses

A non-dilutive, revenue-linked deal is not free money — Function still has to repay General Catalyst out of future revenue, with a built-in return for the fund, which functions economically closer to structured debt than a gift. If Function's member growth or retention slows, that repayment obligation doesn't disappear the way a down round simply resets expectations; it becomes a fixed claim on future cash flow regardless of how the underlying business performs. The lack of an updated revenue figure since the $100 million run-rate estimate from February 2025 — even as membership has more than doubled — is also a gap worth noting: a doubling of subscribers without a matching revenue disclosure could reflect discounting, lower-tier plans, or simply a company choosing not to update the number, and there's no public data to distinguish between those explanations.

There's also a category-wide risk: preventive health and longevity testing has drawn a wave of well-funded entrants, and clinical bodies have periodically questioned the evidence base for routine whole-body scanning and broad biomarker panels in people without symptoms, arguing they can generate false positives and unnecessary follow-up procedures. That's a genuine scientific debate this category hasn't resolved, and it sits underneath every valuation in this table.

The Bottom Line

Function Health added $450 million in growth capital without giving up equity or resetting its $2.5 billion valuation — a larger check, structured to leave the cap table exactly where the November 2025 Series B left it. That's a capital-efficient way to fund growth, but it also means the company still hasn't shown the market an updated valuation that reflects however much its member base has grown since. The next real re-rating moment is a priced round, not a revenue-linked facility — and that's when the market finds out whether 500,000-plus members support a number closer to Function's $2.5 billion or Neko's roughly $7 billion.